Engineers Gate Manager’s Bicycle Therapeutics BCYC Stock Holding History

Engineers Gate Manager’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,400	Closed	-$164K	–	2245
2026 Q1	$164K	Buy	35,400 +11,353	+47%	+$64.9K	﹤0.01%	1954
2025 Q4	$170K	Buy	24,047 +10,626	+79%	+$78.3K	﹤0.01%	1836
2025 Q3	$104K	Sell	13,421 -1,981	-13%	-$15K	﹤0.01%	2003
2025 Q2	$107K	Buy	+15,402	New	+$123K	﹤0.01%	1986
2023 Q4	–	Sell	-16,076	Closed	-$323K	–	1970
2023 Q3	$323K	Buy	+16,076	New	+$368K	0.01%	1283
2022 Q2	–	Sell	-7,770	Closed	-$341K	–	1910
2022 Q1	$341K	Buy	+7,770	New	+$363K	0.01%	1310

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Engineers Gate Manager's BCYC Position: Q2 2026 in Review

Engineers Gate Manager sold out of Bicycle Therapeutics (BCYC) in Q2 2026, closing a stake of 35,400 shares — an estimated $164K sold.

Engineers Gate Manager first reported a position in BCYC in Q1 2022 and held it in 6 quarters. The position peaked at $341K in Q1 2022. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Engineers Gate Manager reported no remaining Bicycle Therapeutics position as of Q2 2026 after selling out during the quarter.
Engineers Gate Manager sold 35,400 Bicycle Therapeutics shares in Q2 2026, an estimated $164K.
Engineers Gate Manager first reported a position in Bicycle Therapeutics in Q1 2022 and held it in 6 quarters.
Engineers Gate Manager's Bicycle Therapeutics position peaked at $341K in Q1 2022.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.